Tourmaline Bio, Inc. (TRML)

13.84 -0.72 (-4.93%) As of 02:10PM EDT. Market open.

Tourmaline Bio, Inc.

27 West 24th Street
Suite 702
New York, NY 10010
United States
646-481-9832
https://www.tourmalinebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 44

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Sandeep C. Kulkarni M.D.	Co-Founder, CEO & Director	753.02k	N/A	1982
Dr. Yung H. Chyung M.D.	Chief Medical Officer	624.63k	N/A	1977
Dr. Kevin B. Johnson M.B.A., Ph.D.	Chief Regulatory Officer	555.84k	N/A	1964
Mr. Ryan Robinson CPA	VP of Finance, Controller & Interim CFO	N/A	N/A	1988
Dr. Susan Dana Jones Ph.D.	Chief Technology Officer	N/A	N/A	1960
Mr. W. Bradford Middlekauff J.D.	Chief Business Officer, General Counsel & Corporate Secretary	N/A	N/A	1962
Ms. Kimberly Piorkowski	Vice President of People, Culture and Compliance	N/A	N/A	N/A
Mr. Ryan Iarrobino	SVP of Product Development	N/A	N/A	N/A
Ms. Dora Rau	Senior Vice President & Head of Quality	N/A	N/A	N/A
Mr. Gerhard Hagn Pharm.D.	Senior VP and Head of Commercial & Business Development	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Corporate Governance

Tourmaline Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.